Skip to main content
. 2023 Mar 16;29(11):2052–2065. doi: 10.1158/1078-0432.CCR-22-3642

Figure 2.

Figure 2. Transcriptional features that associate with PD or SD status after combination therapy in UC tumors. A, Expression profile (Z-score) of bladder tumor subtype marker genes in pretreatment UC tumors. Tissue origin of tumors are provided. B, Gene expression of GSEA Hallmark pathways comparing available PD and SD tumors at pretreatment and posttreatment timepoints. C, Deconvolution of immune cell type abundance in tumors from bulk tumor RNA-seq using quanTIseq. Statistical significance was calculated by using mixed effect beta regression followed by Likelihood Ratio Test. P values were corrected for multiple comparisons with Benjamini–Hochberg method. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

Transcriptional features that associate with PD or SD status after combination therapy in UC tumors. A, Expression profile (Z-score) of bladder tumor subtype marker genes in pretreatment UC tumors. Tissue origin of tumors are provided. B, Gene expression of GSEA Hallmark pathways comparing available PD and SD tumors at pretreatment and posttreatment timepoints. C, Deconvolution of immune cell type abundance in tumors from bulk tumor RNA-seq using quanTIseq. Statistical significance was calculated by using mixed-effect beta regression followed by Likelihood Ratio Test. P values were corrected for multiple comparisons with Benjamini–Hochberg method. *, P < 0.05; **, P < 0.01; ***, P < 0.001.